Roche NimbleGen and Affymetrix Expand Licensing Agreement
News Mar 13, 2008
Roche NimbleGen Inc., a company of Roche Applied Science, and Affymetrix Inc. announced that they have expanded the terms of the license to a number of Affymetrix patents originally granted in October 2006. The expanded license now provides certain diagnostic rights for array-based DNA copy number analysis and array-based re-sequencing in addition to covering the manufacture, use and sale of nucleic acid microarrays and related products and services in the research field. Financial details of the expanded license were not disclosed.
Roche NimbleGen is a leading innovator, manufacturer and supplier of a proprietary suite of DNA microarrays, consumables, instruments and services. Roche NimbleGen uniquely produces high-density arrays of long oligo probes that provide greater information content and higher data quality necessary for studying the full diversity of genomic and epigenomic variation. The improved performance is made possible by Roche NimbleGen’s proprietary Maskless Array Synthesis (MAS) technology, which uses digital light processing and rapid, high-yield photochemistry to synthesize long oligo, high-density DNA microarrays with extreme flexibility.
Diagnosing Immunity to Ebola With Paper Tests & SmartphonesNews
A promising new approach to detect immunity to Ebola virus infection has been developed by researchers from i-sense in a collaboration between UCL and Imperial College London.READ MORE
New Technique Eases Production, Customization of Soft RoboticsNews
By helping rubber and plastic stick together under pressure, University of Nebraska-Lincoln chemists have simplified the production of small fluid-carrying channels that can drive movement in soft robotics and enable chemical analyses on microscopic scales.READ MORE
New Preservation Method Maintains Viable CTCs for up to 72 HoursNews
A new blood stabilization method significantly prolongs the lifespan of blood samples for microfluidic sorting and transcriptome profiling of rare circulating tumor cells.READ MORE